Want to see LFMD full AI Analyst Report?
LifeMD (LFMD) AI Stock Analysis
LifeMD
(NASDAQ:LFMD)
The score is primarily held down by weak financial performance—ongoing losses, TTM revenue decline, and a return to negative operating/free cash flow. Technicals also weigh on the score, with the stock below major moving averages and negative MACD despite oversold momentum signals. Offsetting factors include a more constructive earnings outlook (guided return to adjusted-EBITDA profitability in H2) and positive partnership momentum (AT&T), but these are not yet sufficient to overcome current profitability and cash-burn risks.
LifeMD (LFMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $118.23M
- Dividend Yield
- ―
- Average Volume (3M)
- 817.28K
- Price to Earnings (P/E)
- -4.8
- Beta (1Y)
- 1.47
- Revenue Growth
- -16.73%
- EPS Growth
- -143.95%
- Country
- US
- Employees
- 350
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
LifeMD Business Overview & Revenue Model
Company Description
LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, incl...
How the Company Makes Money
LifeMD primarily generates revenue by selling healthcare services delivered through its telehealth platforms. Key revenue streams include: (1) Patient fees for virtual medical visits and clinician services, which may be charged on a per-visit basis a...
LifeMD Earnings Call Summary
The call presented a mix of strategic progress and near-term financial pressure. Positive operational signs include a high recurring revenue mix (84%), expanding gross margins (~89%), meaningful reductions in marketing and G&A, strong growth in women's health (134% QoQ), improving unit economics in RexMD, a scaling high-margin pharmacy (≈90% gross margin), expanding insurance reach (~175M covered lives), and partnerships such as XYOSTED and integrations with Lilly/NovoCare. Offsetting these positives were a Q2 adjusted EBITDA loss (~$3.5M), GAAP net loss ($7.9M), sequential revenue declines (~6%), pressured cash ($25.1M), elevated acquisition costs earlier in the quarter, and near-term investments and timing risks tied to new initiatives. Management expects a return to adjusted EBITDA profitability in Q3 and stronger results in Q4, but several initiatives require upfront investment and carry execution/timing risk.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management revised 2026 guidance to full‑year revenue of $205.5–$212.5M and adjusted EBITDA of (‑$6M) to breakeven, while guiding Q3 revenue of $48–$51M with adjusted EBITDA of (‑$1M) to $2M and Q4 revenue of $60–$64M with adjusted EBITDA of $3–$6M; they expect to return to adjusted‑EBITDA profitability in Q3 and to exit Q4 at an implied annualized run‑rate of roughly $250M revenue and ~$22M adjusted EBITDA (midpoints), equating to a high‑single‑digit to ~10% exit adjusted‑EBITDA margin (modestly below the prior $25M annualized target). The revision reflects the Q1/Q2 shortfall (Q2 actuals: $47.3M revenue and ~($3.5M) adjusted EBITDA), the $39 introductory weight‑management pricing impact, and planned investments including a $2–$3M XYOSTED launch spend in 2026; quarter‑end cash was $25.1M.
LifeMD Financial Statement Overview
Summary
Income statement remains weak with ongoing losses (TTM net margin -11.2%) and negative EBIT/EBITDA margins, alongside TTM revenue contraction (-6.8%). Cash flow is a major concern with negative TTM operating cash flow (-$9.5M) and negative free cash flow (-$6.8M), signaling renewed cash burn. Balance sheet leverage appears manageable (TTM debt-to-equity ~0.76), but equity volatility and inconsistent profitability keep financial risk elevated.
Income Statement
38NegativeBalance Sheet
45NeutralCash Flow
34Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 204.48M | 194.06M | 212.45M | 152.55M | 119.03M | 92.88M |
| Gross Profit | 175.67M | 154.76M | 188.39M | 133.65M | 100.37M | 74.88M |
| EBITDA | -11.18M | -1.52M | -6.65M | -8.21M | -35.92M | -57.43M |
| Net Income | -21.26M | -7.11M | -18.88M | -20.60M | -45.54M | -60.90M |
Balance Sheet | ||||||
| Total Assets | 59.89M | 70.41M | 72.46M | 58.48M | 25.67M | 49.92M |
| Cash, Cash Equivalents and Short-Term Investments | 25.14M | 36.79M | 35.00M | 33.15M | 3.96M | 41.33M |
| Total Debt | 6.02M | 6.32M | 25.10M | 18.93M | 4.13M | 1.85M |
| Total Liabilities | 51.93M | 47.25M | 76.51M | 52.91M | 32.97M | 24.10M |
| Stockholders Equity | 7.97M | 23.16M | -5.49M | 3.51M | -6.83M | 26.85M |
Cash Flow | ||||||
| Free Cash Flow | -7.19M | -1.24M | 5.98M | 86.95K | -35.83M | -36.49M |
| Operating Cash Flow | -9.91M | 8.28M | 17.51M | 8.82M | -22.94M | -33.09M |
| Investing Cash Flow | 9.78M | 6.91M | -11.54M | -8.73M | -13.91M | -3.40M |
| Financing Cash Flow | -10.96M | -13.41M | -4.12M | 29.10M | -528.20K | 68.64M |
LifeMD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFMD, the sentiment is Neutral. The current price of 2.45 is above the 20-day moving average (MA) of 2.32, below the 50-day MA of 2.76, and below the 200-day MA of 3.64, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 49.63 is Neutral, neither overbought nor oversold. The STOCH value of 67.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LFMD.
LifeMD Risk Analysis
LifeMD disclosed 45 risk factors in its most recent earnings report. LifeMD reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksLifeMD Peers Comparison
Overall Rating
PETS48Neutral- LFMD42Neutral
YI40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| PETS | 48Neutral | $26.01M | -0.90 | -91.67% | ― | -19.67% | 34.91% |
| LFMD | 42Neutral | $105.08M | -4.82 | -179.12% | ― | -16.73% | -143.95% |
| YI | 40Underperform | $26.53M | -1.68 | 23.64% | ― | -23.90% | -45.45% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LFMD | Lifemd, Inc. | 2.45 | -2.81 | -53.42% | |
| PETS | Petmed Express | 1.24 | -1.21 | -49.39% | |
| YI | 111, Inc. | 3.00 | -1.29 | -30.07% |
LifeMD Corporate Events
LifeMD, AT&T Partner to Expand Virtual Care Access
PositiveOn September 15, 2026, LifeMD announced an exclusive collaboration with AT&T that makes LifeMD’s virtual care and pharmacy platform available as a complimentary membership to eligible AT&T wireless and fiber customers. The partnership i...
LifeMD Updates Q2 Results and Subscription Growth Outlook
PositiveLifeMD, Inc. (Nasdaq: LFMD) is a U.S.-based provider of virtual primary care and pharmacy services, operating subscription-based telehealth programs across areas such as weight management and women’s health. The company emphasizes longer-durati...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026